RecruitingPHASE1, PHASE2NCT07219576

Retifanlimab and Ruxolitinib In Solid Malignancies

Studying Acquired cystic disease-associated renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of California, San Diego
Principal Investigator
Rana McKay, MD
University of California, San Diego
Intervention
Ruxolitinib(drug)
Enrollment
40 enrolled
Eligibility
All sexes
Timeline
20262029

Study locations (1)

Collaborators

Incyte Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07219576 on ClinicalTrials.gov

Other trials for Acquired cystic disease-associated renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Acquired cystic disease-associated renal cell carcinoma

← Back to all trials